A PROSPECTIVE STUDY OF ANTI-HCV POSITIVE BLOOD DONORS

大约0.6%的志愿捐赠者被发现 有丙型肝炎病毒抗体(抗-丙型肝炎病毒)，占主导地位 输血相关性肝炎(TAH)的病因一些捐赠者 通过重组免疫印迹试验确定为真阳性 (RIBA)，有些是假阳性，有些是RIBA不确定的。 这项研究将在每个研究中招募至少100名抗-丙型肝炎病毒阳性捐赠者 丙型肝炎病毒的RIBA分类和流行病学危险因素比较 获取和相关肝病的程度。初步 分析显示，至少70%的RIBA阳性捐赠者 公认的非肠外危险因素，主要是静脉注射药物的使用 不到5%的对照组。这些风险因素本应排除 这些人没有捐赠，但没有这样做，这表明 有必要修订捐献者筛选程序。约80%的 无症状RIBA阳性献血者有慢性 肝炎和80%的人也检测到了丙型肝炎病毒RNA。

Approximately 0.6% of the volunteer donor population has been found to have antibody to the hepatitis C virus (anti-HCV), the predominant cause of transfusion associated hepatitis (TAH). Some of the donors are true positive as determined by a recombinant immunoblot assay (RIBA) and some are false positives and some are RIBA indeterminate. This study will enroll at least 100 anti-HCV positive donors in each of the RIBA categories and compare epidemiologic risk factors for HCV acquisition and the extent of associated liver disease. Preliminary analysis reveals that at least 70% of RIBA positive donors have recognized parenteral risk factors, primarily IV drug use compared to less than 5% of controls. These risk factors should have excluded these individuals from donation, but failed to do so indicating the need for revision of donor screening procedures. Approximately 80% of asymptomatic RIBA positive donors have biochemical evidence of chronic hepatitis and 80% also have detectable HCV RNA.